Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Could Earn Up to $24M in New Roche Pact

NEW YORK, March 1 (GenomeWeb News) - Roche and MorphoSys, a German synthetic antibodies producer, have expanded their six-year partnership to develop therapeutic antibodies in oncology, the companies said today.


The firms will collaborate on two new antibody programs in oncology, from which MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than €10 million ($11.9 million) per program, plus potential royalties, according to the companies.


The companies also said that Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.


The new agreement is expanded from a collaboration on Alzheimer's disease that Roche and MorphoSys began in 2000.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.